Search
Bivalirudin
go.drugbank.com/drugs/DB00006ApprovedInvestigationalOnce bound to the active site, thrombin cannot activate fibrinogen into fibrin, the crucial step in the formation of thrombus. It is administered intravenously.
Itraconazole
go.drugbank.com/drugs/DB01167ApprovedInvestigational[A34257] It is a 1:1:1:1 racemic mixture of four diastereomers, made up of two enantiomeric pairs, each possessing three chiral centers.
Categories: Metabolic Side Effects of Drugs and SubstancesAminoglutethimide
go.drugbank.com/drugs/DB00357ApprovedWithdrawnAn aromatase inhibitor that produces a state of "medical" adrenalectomy by blocking the production of adrenal steroids. It also blocks the conversion of androgens to estrogens. Aminoglutethimide has been used in the treatment of advanced...
Framycetin
go.drugbank.com/drugs/DB00452ApprovedInvestigationalA component of neomycin that is produced by Streptomyces fradiae. On hydrolysis it yields neamine and neobiosamine B. (From Merck Index, 11th ed)
Exemestane
go.drugbank.com/drugs/DB00990ApprovedInvestigationalIt irreversibly binds to the active site of the enzyme resulting in permanent inhibition.
Kanamycin
go.drugbank.com/drugs/DB01172ApprovedInvestigationalVet approvedWithdrawnKanamycin (also known as kanamycin A) is an aminoglycoside bacteriocidal antibiotic, available in oral, intravenous, and intramuscular forms, and used to treat a wide variety of infections. Kanamycin is isolated from the bacterium Strept...
Tamoxifen
go.drugbank.com/drugs/DB00675ApprovedInvestigational[L7799,L7802] Tamoxifen may no longer be the preferred treatment for these types of cancers as patients generally have better survival, side effect profiles, and compliance with [anastrozole].
Olanzapine
go.drugbank.com/drugs/DB00334ApprovedInvestigationalThe second-generation antipsychotics were introduced in the 90s and quickly gained traction due to their impressive efficacy, reduced risk for extrapyramidal side effects and reduced susceptibility to
Products: OLANZAPIN PUR 10MG TABLOsimertinib
go.drugbank.com/drugs/DB09330ApprovedInvestigationalIn contrast, third-generation inhibitors are specific for the gate-keeper T790M mutations which increases ATP binding activity to EGFR and result in poor prognosis for late-stage disease. … [A7928] Development of third-generation EGFR-TKIs, such as osimertinib, has been in response to altered tumour resistance patterns following treatment and toxic side effects that impact patient quality
Thiopental
go.drugbank.com/drugs/DB00599ApprovedInvestigationalVet approvedWithdrawnIt does not produce any excitation but has poor analgesic and muscle relaxant properties. Small doses have been shown to be anti-analgesic and lower the pain threshold.